Contents
Contents
EXECUTIVE SUMMARY ..................................................................................................................... 1 Cancer Care ..................................................................................................................................... 2 Oncology market trends ................................................................................................................... 3 EARLY DIAGNOSIS IS THE KEY TO BETTER , MORE AFFORDABLE CANCER CARE .................................... 5 Current status of screening and early diagnosis ................................................................................. 7 The challenges to overcome for future tests ..................................................................................... 9 Future outlook and progress ........................................................................................................... 11 Early diagnosis market overview ...................................................................................................... 17 Key takeaways ................................................................................................................................ 18 COMPANION DIAGNOSTICS DRIVE BETTER OUTCOMES .................................................................... 20 Current status of CDx ...................................................................................................................... 20 Substantial scientific , technical , and other challenges ....................................................................... 24 Future outlook and progress ........................................................................................................... 25 Market overview ............................................................................................................................. 27 RT STILL DOMINATES WHILST PT AWAITS WIDESPREAD ADOPTION .................................................. 29 Current Status of RT ........................................................................................................................ 30 Challenges to address for radiotherapy ............................................................................................ 31 Future Outlook ............................................................................................................................... 35 Key takeaways ................................................................................................................................ 37 INCUMBENT EXPANDING ROBOTIC SURGERY MONOPOLY ................................................................ 39 Current status of robotic surgery in oncology ................................................................................... 40 Challenges to overcome in robotic surgery ...................................................................................... 44 Future outlook ................................................................................................................................ 45 RADIOPHARMACEUTICALS DRIVE PRECISION MEDICINE ................................................................... 47 Radiopharmaceutical combinations are potential blockbusters ......................................................... 48 Current status and progress ............................................................................................................ 49 Market overview ............................................................................................................................. 50 Key takeaway .................................................................................................................................. 52 IMMUNO-ONCOLOGY IS AT THE CORE OF CANCER THERAPY ............................................................ 54 ICI REMAIN KEY IN THE IMMUNO-ONCOLOGY .................................................................................. 58 The current status of ICIs ................................................................................................................. 58 Challenges for ICI to address ........................................................................................................... 60 The future and progress of ICI innovation ........................................................................................ 61 Key takeaways ................................................................................................................................ 64 BISPECIFICS CREATE MULTI-MODEL IMMUNE RESPONSES ................................................................ 66 Current Status of the bispecifics market ........................................................................................... 66 Challenges to address for development of bispecifics ....................................................................... 68 Future directions of the bispecific market landscape ........................................................................ 70 Key takeaways ................................................................................................................................ 71 NOVEL LINKERS CRUCIAL TO IMPROVED ADC EFFICACY .................................................................... 72 Current status ................................................................................................................................. 72 Future outlook and market overview ............................................................................................... 74 TRANSITION OF CAR-T TO ALLOGENIC DRIVING UPTAKE ................................................................... 76 Current status ................................................................................................................................. 76 Future outlook and market overview ............................................................................................... 78 RENAISSANCE OF CANCER VACCINE HYPOTHESIS ............................................................................. 79 Current status ................................................................................................................................. 80 Peptide based antigens and mRNA the focus of Cancer vaccines ....................................................... 80 Challenges for cancer vaccines ........................................................................................................ 83 Future outlook and market overview ............................................................................................... 84 TABLE OF FIGURES .......................................................................................................................... 86 TABLE OF TABLES ............................................................................................................................ 88 REFERENCES ................................................................................................................................... 89
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .